JPMorgan analyst Brian Cheng reiterates Overweight ratings on Roivant Sciences (ROIV) and Immunovant (IMVT) following the recent share weakness, saying fundamentals remain solid for both companies. While Immunovant operates independently, both stories are “highly intertwined,” the analyst tells investors in a research note. The firm continues to look for visibility on Roivant’s plan to deploy its capital. Without clarity on the timing of the next strategic steps, sentiment around Immunovant will need time to improve, contends JPMorgan.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Tourmaline Bio might see weakness today after Roche MG data, says Truist
- Roivant Sciences management to meet with Cantor Fitzgerald
- 5 Best Mid-Cap Stocks to Buy Now, According to Analysts – February 2024
- Wolfe starts Roivant at Outperform, notes robust balance sheet
- Roivant Sciences initiated with an Outperform at Wolfe Research
